Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists

ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‑1 RAs) play a pivotal role in treating type 2 diabetes. Despite their widespread use, their dermatological manifestations remain under‐recognized, hence the interest of this systematic review. Objectives This systematic review aims to assess dermatological manifestations associated with GLP‐1 RA therapy, highlighting both adverse effects and potential therapeutic benefits. Methods Following the PRISMA guidelines, articles that evaluated dermatological outcomes in patients receiving GLP‑1 RAs were systematically searched using PubMed and ScienceDirect databases. Only randomized controlled trials (RCTs) and observational studies involving human subjects were included. Results Hair loss was the most significant side effect, unlike the usually reported injection‐site reactions or lipodystrophy. Interestingly, several studies found that liraglutide and semaglutide therapy improved psoriasis lesions. Conclusions The most frequent side effect associated with GLP1‐RA use in this review appeared to be hair loss. Importantly, some GLP1‐RAs have been shown to improve psoriatic lesions.